APA (7th ed.) Citation

R, K., Y, Z., J, T., B, D., T, S., K, F., & V, B. (2025). Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease. MAbs, 17(1), 2585616. https://doi.org/10.1080/19420862.2025.2585616

Chicago Style (17th ed.) Citation

R, Kaplan, Zhao Y, Tsai J, Dickinson B, Swanson T, Foster K, and Bedian V. "Preclinical Pharmacology, Pharmacokinetics, and Pharmacodynamics of Veligrotug, a Full Antagonist Antibody to the IGF-1 Receptor in Development for Thyroid Eye Disease." MAbs 17, no. 1 (2025): 2585616. https://doi.org/10.1080/19420862.2025.2585616.

MLA (9th ed.) Citation

R, Kaplan, et al. "Preclinical Pharmacology, Pharmacokinetics, and Pharmacodynamics of Veligrotug, a Full Antagonist Antibody to the IGF-1 Receptor in Development for Thyroid Eye Disease." MAbs, vol. 17, no. 1, 2025, p. 2585616, https://doi.org/10.1080/19420862.2025.2585616.